Relationship between the effectiveness of pembrolizumab monotherapy and ABO blood type in recurrent and metastatic squamous cell carcinoma of the head and neck
Abstract Background Recent studies have suggested a correlation between ABO blood type and the effectiveness of immune checkpoint inhibitors. However, the relationship between ABO blood type and response to pembrolizumab monotherapy as first-line treatment for squamous cell carcinoma of the head and...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Springer
2025-07-01
|
| Series: | Discover Oncology |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/s12672-025-03105-x |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849331904101220352 |
|---|---|
| author | Shogen Boku Tatsuki Ikoma Tomoyo Yasuda Nobuhiro Shibata Tomofumi Sakagami Kensuke Suzuki Takuo Fujisawa Hiroshi Iwai Masashi Kanai |
| author_facet | Shogen Boku Tatsuki Ikoma Tomoyo Yasuda Nobuhiro Shibata Tomofumi Sakagami Kensuke Suzuki Takuo Fujisawa Hiroshi Iwai Masashi Kanai |
| author_sort | Shogen Boku |
| collection | DOAJ |
| description | Abstract Background Recent studies have suggested a correlation between ABO blood type and the effectiveness of immune checkpoint inhibitors. However, the relationship between ABO blood type and response to pembrolizumab monotherapy as first-line treatment for squamous cell carcinoma of the head and neck (SCCHN) remains unclear. Method We retrospectively analyzed the patients who were treated with pembrolizumab as the first-line treatment for locally advanced, recurrent, or metastatic SCCHN between May 2020 and September 2024. Result A total of 38 cases were analysed in this study. The ABO blood types of patients were as follows: 15 (39.5%) were type A, 9 (23.7%) were type B, 3 (7.9%) were type AB, and 11 (28.9%) were type O. Median Overall survival (OS) by blood type was 28.9 months for type A, 7.8 months for type B, 45.6 months for type O, and 21.4 months for type AB. The OS of B antigen-positive group (B group; B or AB) was significantly poorer than that of B antigen-negative group (non-B group; A or O) (7.8 months [95% CI, 3.0-16.4] vs. 28.9 months [95% CI, 10.7–45.6], p = 0.0022). Progression-free survival (PFS) was 2.6 (95% CI, 1.2–7.6) months vs. 7.2 (95% CI, 3.5–24.1) months (p = 0.06), overall response rate (ORR) was 25.0 vs. 46.2% (p = 0.29) and disease control rate (DCR) was 41.7 vs. 76.9% (p = 0.06), respectively. Conclusion In this cohort, the presence of B antigen provides a significant disadvantage in terms of survival in patients using pembrolizumab for SCCHN. |
| format | Article |
| id | doaj-art-83d39ebcdb854b4b937d207df2bc6e97 |
| institution | Kabale University |
| issn | 2730-6011 |
| language | English |
| publishDate | 2025-07-01 |
| publisher | Springer |
| record_format | Article |
| series | Discover Oncology |
| spelling | doaj-art-83d39ebcdb854b4b937d207df2bc6e972025-08-20T03:46:23ZengSpringerDiscover Oncology2730-60112025-07-011611910.1007/s12672-025-03105-xRelationship between the effectiveness of pembrolizumab monotherapy and ABO blood type in recurrent and metastatic squamous cell carcinoma of the head and neckShogen Boku0Tatsuki Ikoma1Tomoyo Yasuda2Nobuhiro Shibata3Tomofumi Sakagami4Kensuke Suzuki5Takuo Fujisawa6Hiroshi Iwai7Masashi Kanai8Department of Clinical Oncology, Kansai Medical University HospitalDepartment of Clinical Oncology, Kansai Medical University HospitalDepartment of Clinical Oncology, Kansai Medical University HospitalDepartment of Clinical Oncology, Kansai Medical University HospitalDepartment of Otolaryngology, Head and Neck Surgery, Kansai Medical UniversityDepartment of Otolaryngology, Head and Neck Surgery, Kansai Medical UniversityDepartment of Otolaryngology, Head and Neck Surgery, Kansai Medical UniversityDepartment of Otolaryngology, Head and Neck Surgery, Kansai Medical UniversityDepartment of Clinical Oncology, Kansai Medical University HospitalAbstract Background Recent studies have suggested a correlation between ABO blood type and the effectiveness of immune checkpoint inhibitors. However, the relationship between ABO blood type and response to pembrolizumab monotherapy as first-line treatment for squamous cell carcinoma of the head and neck (SCCHN) remains unclear. Method We retrospectively analyzed the patients who were treated with pembrolizumab as the first-line treatment for locally advanced, recurrent, or metastatic SCCHN between May 2020 and September 2024. Result A total of 38 cases were analysed in this study. The ABO blood types of patients were as follows: 15 (39.5%) were type A, 9 (23.7%) were type B, 3 (7.9%) were type AB, and 11 (28.9%) were type O. Median Overall survival (OS) by blood type was 28.9 months for type A, 7.8 months for type B, 45.6 months for type O, and 21.4 months for type AB. The OS of B antigen-positive group (B group; B or AB) was significantly poorer than that of B antigen-negative group (non-B group; A or O) (7.8 months [95% CI, 3.0-16.4] vs. 28.9 months [95% CI, 10.7–45.6], p = 0.0022). Progression-free survival (PFS) was 2.6 (95% CI, 1.2–7.6) months vs. 7.2 (95% CI, 3.5–24.1) months (p = 0.06), overall response rate (ORR) was 25.0 vs. 46.2% (p = 0.29) and disease control rate (DCR) was 41.7 vs. 76.9% (p = 0.06), respectively. Conclusion In this cohort, the presence of B antigen provides a significant disadvantage in terms of survival in patients using pembrolizumab for SCCHN.https://doi.org/10.1007/s12672-025-03105-xPembrolizumabImmune checkpoint inhibitorHead and neck cancerABO blood type |
| spellingShingle | Shogen Boku Tatsuki Ikoma Tomoyo Yasuda Nobuhiro Shibata Tomofumi Sakagami Kensuke Suzuki Takuo Fujisawa Hiroshi Iwai Masashi Kanai Relationship between the effectiveness of pembrolizumab monotherapy and ABO blood type in recurrent and metastatic squamous cell carcinoma of the head and neck Discover Oncology Pembrolizumab Immune checkpoint inhibitor Head and neck cancer ABO blood type |
| title | Relationship between the effectiveness of pembrolizumab monotherapy and ABO blood type in recurrent and metastatic squamous cell carcinoma of the head and neck |
| title_full | Relationship between the effectiveness of pembrolizumab monotherapy and ABO blood type in recurrent and metastatic squamous cell carcinoma of the head and neck |
| title_fullStr | Relationship between the effectiveness of pembrolizumab monotherapy and ABO blood type in recurrent and metastatic squamous cell carcinoma of the head and neck |
| title_full_unstemmed | Relationship between the effectiveness of pembrolizumab monotherapy and ABO blood type in recurrent and metastatic squamous cell carcinoma of the head and neck |
| title_short | Relationship between the effectiveness of pembrolizumab monotherapy and ABO blood type in recurrent and metastatic squamous cell carcinoma of the head and neck |
| title_sort | relationship between the effectiveness of pembrolizumab monotherapy and abo blood type in recurrent and metastatic squamous cell carcinoma of the head and neck |
| topic | Pembrolizumab Immune checkpoint inhibitor Head and neck cancer ABO blood type |
| url | https://doi.org/10.1007/s12672-025-03105-x |
| work_keys_str_mv | AT shogenboku relationshipbetweentheeffectivenessofpembrolizumabmonotherapyandabobloodtypeinrecurrentandmetastaticsquamouscellcarcinomaoftheheadandneck AT tatsukiikoma relationshipbetweentheeffectivenessofpembrolizumabmonotherapyandabobloodtypeinrecurrentandmetastaticsquamouscellcarcinomaoftheheadandneck AT tomoyoyasuda relationshipbetweentheeffectivenessofpembrolizumabmonotherapyandabobloodtypeinrecurrentandmetastaticsquamouscellcarcinomaoftheheadandneck AT nobuhiroshibata relationshipbetweentheeffectivenessofpembrolizumabmonotherapyandabobloodtypeinrecurrentandmetastaticsquamouscellcarcinomaoftheheadandneck AT tomofumisakagami relationshipbetweentheeffectivenessofpembrolizumabmonotherapyandabobloodtypeinrecurrentandmetastaticsquamouscellcarcinomaoftheheadandneck AT kensukesuzuki relationshipbetweentheeffectivenessofpembrolizumabmonotherapyandabobloodtypeinrecurrentandmetastaticsquamouscellcarcinomaoftheheadandneck AT takuofujisawa relationshipbetweentheeffectivenessofpembrolizumabmonotherapyandabobloodtypeinrecurrentandmetastaticsquamouscellcarcinomaoftheheadandneck AT hiroshiiwai relationshipbetweentheeffectivenessofpembrolizumabmonotherapyandabobloodtypeinrecurrentandmetastaticsquamouscellcarcinomaoftheheadandneck AT masashikanai relationshipbetweentheeffectivenessofpembrolizumabmonotherapyandabobloodtypeinrecurrentandmetastaticsquamouscellcarcinomaoftheheadandneck |